SAN DIEGO, April 2, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis companyin the United States, today announced that it garnered news coverage with a feature story in top national newspaper The Washington Post.
A March 28, 2018 article on The Washington
Medical Marijuana, Inc. was the first company to ever create a global CBD pipeline with its flagship product, Real Scientific Hemp Oil™ (RSHO™), and now has several distribution subsidiaries such as HempMeds®, Kannaway® and Phyto Animal Health. The company also operates in many other countries around the world and was the first to receive historic federal government import approvals for its CBD products in the nations of Brazil, Mexico and Paraguay. The company has since set up distribution subsidiaries in those countries as well.
"We are thrilled to be acknowledged by such a prestigious national publication highlighting Medical Marijuana, Inc. as a leader in the CBD industry," said Medical Marijuana, Inc. CEO Dr. Titus. "This kind of media coverage helps us communicate the health and wellness benefits of CBD, while shedding light on the company's accomplishments."
About Medical Marijuana, Inc.We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
CONTACT:Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 858-264-6600 email@example.com www.cmwmedia.com
View original content:http://www.prnewswire.com/news-releases/top-us-newspaper-the-washington-post-features-medical-marijuana-inc-and-company-ceo-dr-stuart-titus-300622051.html
SOURCE Medical Marijuana, Inc.
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All